5-Jun-2026
Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Globe Newswire (Wed, 3-Jun 7:01 AM ET)
Globe Newswire (Mon, 1-Jun 7:01 AM ET)
Invivyd to Participate in Upcoming Investor Events
Globe Newswire (Wed, 27-May 7:01 AM ET)
Invivyd Reports First Quarter 2026 Financial Results and Recent Business Highlights
Globe Newswire (Thu, 14-May 7:01 AM ET)
Globe Newswire (Mon, 11-May 7:01 AM ET)
Invivyd to Host First Quarter 2026 Financial Results and Corporate Update Call on May 14, 2026
Globe Newswire (Thu, 7-May 7:01 AM ET)
Invivyd Announces Chairman Marc Elia to Speak at POLITICO Health Care Summit
Globe Newswire (Mon, 20-Apr 7:01 AM ET)
Market Chameleon (Thu, 9-Apr 7:44 AM ET)
Globe Newswire (Thu, 9-Apr 7:01 AM ET)
Globe Newswire (Tue, 7-Apr 7:01 AM ET)
Invivyd Inc is a biopharmaceutical company focused on the discovery, development, and commercialization of monoclonal antibody (mAb) therapies for the prevention and treatment of serious viral infectious diseases. Its lead product, PEMGARDA (pemivibart), received emergency use authorization from the U.S. FDA for the pre-exposure prevention of COVID-19 in certain immunocompromised individuals. The company is also developing next-generation antibody candidates, including VYD2311 for COVID-19 and VBY329 for RSV infections, while continuing research on additional antibodies targeting other viral diseases such as measles.
Invivyd trades on the NASDAQ stock market under the symbol IVVD.
As of June 5, 2026, IVVD stock price declined to $1.03 with 4,938,780 million shares trading.
IVVD has a beta of 1.41, meaning it tends to be more sensitive to market movements. IVVD has a correlation of 0.02 to the broad based SPY ETF.
IVVD has a market cap of $303.45 million. This is considered a Small Cap stock.
Last quarter Invivyd reported $14 million in Revenue and -$.13 earnings per share. This fell short of revenue expectation by $-4 million and missed earnings estimates by -$.05.
In the last 3 years, IVVD traded as high as $5.20 and as low as $.35.
The top ETF exchange traded funds that IVVD belongs to (by Net Assets): VTI, XBI, VXF, ITOT, PRFZ.
IVVD has underperformed the market in the last year with a price return of +11.3% while the SPY ETF gained +25.6%. IVVD has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -40.8% and -6.4%, respectively, while the SPY returned +8.5% and -1.1%, respectively.
IVVD support price is $1.04 and resistance is $1.18 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that IVVD shares will trade within this expected range on the day.